Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
Chin Med J (Engl). 2013;126(8):1464-8.
A few inflammatory markers were studied to evaluate their possible prognostic roles in various cancers. The neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are hypothesized to reflect the systemic inflammation. The objective of the present study was to investigate whether or not the pretreatment neutrophil-to-lymphocyte ratio or platelet-to-lymphocyte ratio can predict the survival of patients with cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy.
We performed a retrospective study on cervical cancer patients (FIGO stage Ib2-IIb) who had undergone neoadjuvant chemotherapy and radical hysterectomy at Peking Union Medical College Hospital between January 1999 and December 2010. Data on demographics, clinical prognostic markers and histopathology were collected and analyzed. Univariate and multivariate analyses for prognostic factors were performed.
A total of 111 patients were identified. The median neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios were 2.4 and 142.2, respectively. Overall survival and progression-free survival were neither significantly different between patients with high and low neutrophil-to-lymphocyte ratio (P = 0.149 and P = 0.108) nor in high and low platelet-to-lymphocyte ratio (P = 0.336 and P = 0.510). On multivariate analysis, lymph node status (P = 0.000 and P = 0.007) and lymphovascular space involvement (P = 0.001 and P = 0.001) were independent prognostic factors of progression-free survival and overall survival.
Lymph node status and lymphovascular space involvement were found to be independent prognostic factors for patients with cervical cancer who underwent neoadjuvant chemotherapy and radical hysterectomy. The pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios seemed not to predict the survival of patients with cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy.
一些炎症标志物已被研究用于评估其在各种癌症中的可能预后作用。中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值被认为可以反映全身炎症。本研究旨在探讨新辅助化疗和根治性子宫切除术治疗的宫颈癌患者的治疗前中性粒细胞与淋巴细胞比值或血小板与淋巴细胞比值是否可以预测其生存。
我们对 1999 年 1 月至 2010 年 12 月期间在北京协和医学院医院接受新辅助化疗和根治性子宫切除术的宫颈癌患者（FIGO 分期 Ib2-IIb）进行了回顾性研究。收集并分析了人口统计学、临床预后标志物和组织病理学数据。进行了单因素和多因素预后因素分析。
共确定了 111 例患者。中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值的中位数分别为 2.4 和 142.2。高与低中性粒细胞与淋巴细胞比值之间的总体生存率和无进展生存率均无显著差异（P = 0.149 和 P = 0.108），高与低血小板与淋巴细胞比值之间也无显著差异（P = 0.336 和 P = 0.510）。多因素分析显示，淋巴结状态（P = 0.000 和 P = 0.007）和淋巴管血管间隙浸润（P = 0.001 和 P = 0.001）是无进展生存率和总体生存率的独立预后因素。
淋巴结状态和淋巴管血管间隙浸润被发现是接受新辅助化疗和根治性子宫切除术的宫颈癌患者的独立预后因素。治疗前中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值似乎不能预测接受新辅助化疗和根治性子宫切除术治疗的宫颈癌患者的生存。
